What's in Ciusss de L'Est de l'Île de Montréal's pipeline?

Ciusss de L'Est de l'Île de Montréal has 13 drugs in our index: 8 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 3 in Phase 1.

Which companies overlap with Ciusss de L'Est de l'Île de Montréal's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Rambam Health Care Campus, Beijing Tiantan Hospital, Icahn School of Medicine at Mount Sinai, NYU Langone Health.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ciusss-de-l-est-de-l-le-de-montr-al.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Ciusss de L'Est de l'Île de Montréal — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ciusss de L'Est de l'Île de Montréal pipeline: 8 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 0 Phase 3 1 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Intravenous Fentanyl guided by SoC	Intravenous Fentanyl guided by SoC	marketed	Opioid agonist	Mu-opioid receptor (OPRM1)	Pain management, Anesthesia
Carbetocin bolus	Carbetocin bolus	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)	Obstetrics
Bupivacaine Injection	Bupivacaine Injection	marketed	Local anesthetic (amide)	Voltage-gated sodium channels	Anesthesia
intravenous lidocaine (IVL)	intravenous lidocaine (IVL)	marketed	Local anesthetic; Class IB antiarrhythmic	Voltage-gated sodium channels	Cardiovascular; Anesthesia; Pain management
Carbetocin infusion	Carbetocin infusion	marketed	Oxytocin receptor agonist	Oxytocin receptor (OXTR)	Obstetrics/Gynecology
continuous infusion of intravenous ketamine	continuous infusion of intravenous ketamine	marketed	NMDA receptor antagonist	NMDA receptor	Anesthesia, Pain Management, Psychiatry
bolus of intravenous ketamine	bolus of intravenous ketamine	marketed	NMDA receptor antagonist	NMDA receptor	Anesthesia, Analgesia, Psychiatry
Intravenous Fentanyl guided by SoC+NOL	Intravenous Fentanyl guided by SoC+NOL	marketed	Opioid agonist	Mu-opioid receptor (OPRM1)	Anesthesia and Pain Management

Therapeutic area mix

Anesthesia · 1
Anesthesia and Pain Management · 1
Anesthesia, Analgesia, Psychiatry · 1
Anesthesia, Pain Management, Psychiatry · 1
Cardiovascular; Anesthesia; Pain management · 1
Obstetrics · 1
Obstetrics/Gynecology · 1
Oncology · 1
Other · 1
Pain management, Anesthesia · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 3 shared drug classes
Rambam Health Care Campus · 2 shared drug classes
Beijing Tiantan Hospital · 2 shared drug classes
Icahn School of Medicine at Mount Sinai · 2 shared drug classes
NYU Langone Health · 2 shared drug classes
Oslo University Hospital · 2 shared drug classes
Kasr El Aini Hospital · 2 shared drug classes
The University of Texas Health Science Center, Houston · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Ciusss de L'Est de l'Île de Montréal:

Cite this brief

Drug Landscape (2026). Ciusss de L'Est de l'Île de Montréal — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ciusss-de-l-est-de-l-le-de-montr-al. Accessed 2026-05-17.